Abstract
During the process of developing a slow-release formulation of indapamide, researchers created a drug-containing pellet coated with Eudragit® RS100 (Rohm GMbH & Co. KG, Darmstadt, Germany) to control the rate at which the drug was released. The two main variables were the agglomerants used in the pellet preparation and the amount of Eudragit RS100 used to coat them. The optimal outcome was indicated by the greatest number of drug-containing pellets recovered through an 18-to 24-mesh sieve and a satisfactory 24-hour release curve. The kinetics of dissolution fit the Higuchi kinetics model. Stability tests of the drug pellets showed no notable changes in the rate of drug release, related substances (mean byproducts or impurities from interactions or decompositions), and drug content.
Similar content being viewed by others
References
Asmar R, Guez D, Malbezin M, Brault Y, et al. Therapeutic benefit of a low dose of indapamide: results of a double-blind against placebo European controlled study.Arch Mal Coeur Vaiss. 1995; 88:1083–1087.
Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group.J Hypertens. 1998;16:1677–1684.
Leonetti G. Clinical positioning of indapamide sustained release 1.5 mg in management protocols for hypertension.Drugs. 2000;59:27–40.
Sancin P, Caputo O, Cavallari C, et al. Effects of ultrasound-assisted compaction on ketoprofen/ Eudragit RS100 mixtures.Euro J Pharm Sci. 1999;7:207–213.
Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.Eur J Pharm Sci. 2002;16:53–61.
Süslü I, Altinöz S. Two derivative spectrophotometric determinations of indapamide in pharmaceutical dosage forms.J Pharm Biomed Anal. 2002;30:357–364.
Bodea A, Leucuta SE. Optimization of propranolol hydrochloride sustained release pellets using a factorial design.Int J Pharm. 1997;154:49–57.
Kachrimanis K, Ktistis G, Malamataris S. Crystallisation conditions and physicomechanical properties of ibuprofen-Eudragit® RS100 spherical crystal agglomerates prepared by the solventchange technique.Int J Pharm. 1998;173:61–74.
Ketan A, Mehta MS, Kislalioglu W, et al. Release performance of a poorly soluble drug from a novel, Eudragit®-based multi-unit erosion matrix.Int J Pharm. 2001;213:7–12.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jia, W., Qiu, M., Sun, X. et al. Preparation of Indapamide slow-release pellets. Adv Therapy 21, 238–246 (2004). https://doi.org/10.1007/BF02850156
Issue Date:
DOI: https://doi.org/10.1007/BF02850156